Cargando…
P636: A FIRST-IN-HUMAN PHASE 1 STUDY OF ORAL LOXO-338, A SELECTIVE BCL2 INHIBITOR, IN PATIENTS WITH ADVANCED HEMATOLOGIC MALIGNANCIES
| Autores principales: | , , , , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Lippincott Williams & Wilkins
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10429384/ http://dx.doi.org/10.1097/01.HS9.0000969448.21678.5f |
| _version_ | 1785090699105927168 |
|---|---|
| author | Kwiatek, Michal Subramanian Guru Murthy, Guru Hoffmann, Marc Roeker, Lindsey Tessoulin, Benoit Danilov, Alexey Alencar, Alvaro J. Shah, Nirav N. Ghesquieres, Herve Le Gouill, Steven Jurczak, Wojciech R. Mato, Anthony Patel, Vishalkumar Guo-Avrutin, Yingying Pauff, James M. Kazmierczak, Maciej |
| author_facet | Kwiatek, Michal Subramanian Guru Murthy, Guru Hoffmann, Marc Roeker, Lindsey Tessoulin, Benoit Danilov, Alexey Alencar, Alvaro J. Shah, Nirav N. Ghesquieres, Herve Le Gouill, Steven Jurczak, Wojciech R. Mato, Anthony Patel, Vishalkumar Guo-Avrutin, Yingying Pauff, James M. Kazmierczak, Maciej |
| author_sort | Kwiatek, Michal |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-10429384 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2023 |
| publisher | Lippincott Williams & Wilkins |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-104293842023-08-17 P636: A FIRST-IN-HUMAN PHASE 1 STUDY OF ORAL LOXO-338, A SELECTIVE BCL2 INHIBITOR, IN PATIENTS WITH ADVANCED HEMATOLOGIC MALIGNANCIES Kwiatek, Michal Subramanian Guru Murthy, Guru Hoffmann, Marc Roeker, Lindsey Tessoulin, Benoit Danilov, Alexey Alencar, Alvaro J. Shah, Nirav N. Ghesquieres, Herve Le Gouill, Steven Jurczak, Wojciech R. Mato, Anthony Patel, Vishalkumar Guo-Avrutin, Yingying Pauff, James M. Kazmierczak, Maciej Hemasphere Posters Lippincott Williams & Wilkins 2023-08-08 /pmc/articles/PMC10429384/ http://dx.doi.org/10.1097/01.HS9.0000969448.21678.5f Text en Copyright © 2023 The Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access Abstract Book distributed under the Attribution-NonCommercial-NoDerivs (CC BY-NC-ND) (https://creativecommons.org/licenses/by-nc-nd/4.0/) which allows third parties to download the articles and share them with others as long as they credit the author and the Abstract Book, but they cannot change the content in any way or use them commercially. |
| spellingShingle | Posters Kwiatek, Michal Subramanian Guru Murthy, Guru Hoffmann, Marc Roeker, Lindsey Tessoulin, Benoit Danilov, Alexey Alencar, Alvaro J. Shah, Nirav N. Ghesquieres, Herve Le Gouill, Steven Jurczak, Wojciech R. Mato, Anthony Patel, Vishalkumar Guo-Avrutin, Yingying Pauff, James M. Kazmierczak, Maciej P636: A FIRST-IN-HUMAN PHASE 1 STUDY OF ORAL LOXO-338, A SELECTIVE BCL2 INHIBITOR, IN PATIENTS WITH ADVANCED HEMATOLOGIC MALIGNANCIES |
| title | P636: A FIRST-IN-HUMAN PHASE 1 STUDY OF ORAL LOXO-338, A SELECTIVE BCL2 INHIBITOR, IN PATIENTS WITH ADVANCED HEMATOLOGIC MALIGNANCIES |
| title_full | P636: A FIRST-IN-HUMAN PHASE 1 STUDY OF ORAL LOXO-338, A SELECTIVE BCL2 INHIBITOR, IN PATIENTS WITH ADVANCED HEMATOLOGIC MALIGNANCIES |
| title_fullStr | P636: A FIRST-IN-HUMAN PHASE 1 STUDY OF ORAL LOXO-338, A SELECTIVE BCL2 INHIBITOR, IN PATIENTS WITH ADVANCED HEMATOLOGIC MALIGNANCIES |
| title_full_unstemmed | P636: A FIRST-IN-HUMAN PHASE 1 STUDY OF ORAL LOXO-338, A SELECTIVE BCL2 INHIBITOR, IN PATIENTS WITH ADVANCED HEMATOLOGIC MALIGNANCIES |
| title_short | P636: A FIRST-IN-HUMAN PHASE 1 STUDY OF ORAL LOXO-338, A SELECTIVE BCL2 INHIBITOR, IN PATIENTS WITH ADVANCED HEMATOLOGIC MALIGNANCIES |
| title_sort | p636: a first-in-human phase 1 study of oral loxo-338, a selective bcl2 inhibitor, in patients with advanced hematologic malignancies |
| topic | Posters |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10429384/ http://dx.doi.org/10.1097/01.HS9.0000969448.21678.5f |
| work_keys_str_mv | AT kwiatekmichal p636afirstinhumanphase1studyoforalloxo338aselectivebcl2inhibitorinpatientswithadvancedhematologicmalignancies AT subramaniangurumurthyguru p636afirstinhumanphase1studyoforalloxo338aselectivebcl2inhibitorinpatientswithadvancedhematologicmalignancies AT hoffmannmarc p636afirstinhumanphase1studyoforalloxo338aselectivebcl2inhibitorinpatientswithadvancedhematologicmalignancies AT roekerlindsey p636afirstinhumanphase1studyoforalloxo338aselectivebcl2inhibitorinpatientswithadvancedhematologicmalignancies AT tessoulinbenoit p636afirstinhumanphase1studyoforalloxo338aselectivebcl2inhibitorinpatientswithadvancedhematologicmalignancies AT danilovalexey p636afirstinhumanphase1studyoforalloxo338aselectivebcl2inhibitorinpatientswithadvancedhematologicmalignancies AT alencaralvaroj p636afirstinhumanphase1studyoforalloxo338aselectivebcl2inhibitorinpatientswithadvancedhematologicmalignancies AT shahniravn p636afirstinhumanphase1studyoforalloxo338aselectivebcl2inhibitorinpatientswithadvancedhematologicmalignancies AT ghesquieresherve p636afirstinhumanphase1studyoforalloxo338aselectivebcl2inhibitorinpatientswithadvancedhematologicmalignancies AT legouillsteven p636afirstinhumanphase1studyoforalloxo338aselectivebcl2inhibitorinpatientswithadvancedhematologicmalignancies AT jurczakwojciech p636afirstinhumanphase1studyoforalloxo338aselectivebcl2inhibitorinpatientswithadvancedhematologicmalignancies AT rmatoanthony p636afirstinhumanphase1studyoforalloxo338aselectivebcl2inhibitorinpatientswithadvancedhematologicmalignancies AT patelvishalkumar p636afirstinhumanphase1studyoforalloxo338aselectivebcl2inhibitorinpatientswithadvancedhematologicmalignancies AT guoavrutinyingying p636afirstinhumanphase1studyoforalloxo338aselectivebcl2inhibitorinpatientswithadvancedhematologicmalignancies AT pauffjamesm p636afirstinhumanphase1studyoforalloxo338aselectivebcl2inhibitorinpatientswithadvancedhematologicmalignancies AT kazmierczakmaciej p636afirstinhumanphase1studyoforalloxo338aselectivebcl2inhibitorinpatientswithadvancedhematologicmalignancies |